Nilotinib Patent Expiry Leaves Door Open For India Generics, Other Markets Could Face Longer Wait

Hetero Likely Planning India Generic

 
• By Vibha Ravi
  
Nilotinib
A Generic To Tasigna Is Much Awaited • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip